S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:LUCD

Lucid Diagnostics (LUCD) Stock Forecast, Price & News

$1.17
-0.19 (-13.97%)
(As of 09/29/2023 ET)
Compare
Today's Range
$1.10
$1.48
50-Day Range
$1.17
$1.65
52-Week Range
$1.10
$2.36
Volume
505,963 shs
Average Volume
72,018 shs
Market Capitalization
$50.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.43

Lucid Diagnostics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
193.4% Upside
$3.43 Price Target
Short Interest
Healthy
0.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.02mentions of Lucid Diagnostics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$5,821 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.14) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

779th out of 973 stocks

Surgical & Medical Instruments Industry

83rd out of 101 stocks


LUCD stock logo

About Lucid Diagnostics (NASDAQ:LUCD) Stock

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

LUCD Price History

LUCD Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Q2 2023 Lucid Diagnostics Inc Earnings Call
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Lucid Diagnostics Inc.
8-K: Lucid Diagnostics Inc.
Q1 2023 PAVmed Inc Earnings Call
Where Lucid Diagnostics Stands With Analysts
Lucid Diagnostics (LUCD) Receives a Buy from Needham
Preview: Lucid Diagnostics's Earnings
See More Headlines
Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

LUCD Company Calendar

Last Earnings
8/14/2023
Today
9/29/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LUCD
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.43
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.80
Forecasted Upside/Downside
+198.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-56,170,000.00
Net Margins
-7,873.64%
Pretax Margin
-7,175.92%

Debt

Sales & Book Value

Annual Sales
$380,000.00
Book Value
$0.59 per share

Miscellaneous

Free Float
41,311,000
Market Cap
$49.90 million
Optionable
Not Optionable
Beta
1.81
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Lishan Aklog M.D. (Age 57)
    Chairman & CEO
  • Mr. Dennis M. McGrath CPA (Age 66)
    Chief Financial Officer
  • Mr. Shaun M. O'Neill M.B.A. (Age 41)
    Exec. VP & COO
  • Dr. Sanford D. Markowitz M.D.
    Ph.D., Cofounder & Strategic Advisor, Member of the Medical Advisor Board
  • Dr. Joseph Willis M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Dr. Amitabh Chak M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Richard D. Yazbeck
    Chief Technology Officer
  • Dr. Suman M. Verma M.D.
    Ph.D., Chief Scientific Officer
  • Dr. Brian J. deGuzman M.D. (Age 58)
    Chief Compliance Officer
  • Mr. Michael Adam Gordon (Age 49)
    Gen. Counsel & Sec.













LUCD Stock - Frequently Asked Questions

Should I buy or sell Lucid Diagnostics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LUCD shares.
View LUCD analyst ratings
or view top-rated stocks.

What is Lucid Diagnostics' stock price forecast for 2023?

3 brokerages have issued twelve-month target prices for Lucid Diagnostics' shares. Their LUCD share price forecasts range from $2.80 to $4.00. On average, they anticipate the company's stock price to reach $3.43 in the next year. This suggests a possible upside of 198.6% from the stock's current price.
View analysts price targets for LUCD
or view top-rated stocks among Wall Street analysts.

How have LUCD shares performed in 2023?

Lucid Diagnostics' stock was trading at $1.36 on January 1st, 2023. Since then, LUCD stock has decreased by 15.4% and is now trading at $1.15.
View the best growth stocks for 2023 here
.

When is Lucid Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our LUCD earnings forecast
.

How were Lucid Diagnostics' earnings last quarter?

Lucid Diagnostics Inc. (NASDAQ:LUCD) posted its quarterly earnings data on Monday, August, 14th. The company reported ($0.26) earnings per share for the quarter. The company earned $0.16 million during the quarter. Lucid Diagnostics had a negative net margin of 7,873.64% and a negative trailing twelve-month return on equity of 371.88%.

When did Lucid Diagnostics IPO?

(LUCD) raised $75 million in an IPO on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share.

What is Lucid Diagnostics' stock symbol?

Lucid Diagnostics trades on the NASDAQ under the ticker symbol "LUCD."

How do I buy shares of Lucid Diagnostics?

Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lucid Diagnostics' stock price today?

One share of LUCD stock can currently be purchased for approximately $1.15.

How much money does Lucid Diagnostics make?

Lucid Diagnostics (NASDAQ:LUCD) has a market capitalization of $49.90 million and generates $380,000.00 in revenue each year. The company earns $-56,170,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Lucid Diagnostics have?

The company employs 2,021 workers across the globe.

How can I contact Lucid Diagnostics?

The official website for the company is www.luciddx.com. The company can be reached via phone at 212-949-4319 or via email at pavmed@lavoiehealthscience.com.

This page (NASDAQ:LUCD) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -